__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
Luxturna is indicated for the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.1
A one-time* gene therapy for your patients with an RPE65-IRD1
*The individual administration procedure to each eye is performed on separate days within a close interval, but no fewer than 6 days apart.
IRD, inherited retinal dystrophy; RPE, retinal pigment epithelium.
References
- Novartis Pharmaceuticals UK Ltd. Luxturna® (voretigene neparvovec) Summary of Product Characteristics.
- Menghini M et al. Expert Opin Orphan Drugs 2020;8(2–3):67–78.
- Novartis. Novartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal disease. Available at: https://www.novartis.com/news/media-releases/novartis-announces-landmark... [Accessed March 2023].
- Russell S et al. Lancet 2017;390(10097):849–860.
- Luxturna EMA Assessment Report. EMA/CHMP/700911/2018. 2018. Available at: https://www.ema.europa.eu/en/documents/assessment-report/luxturna-epar-p.... [Accessed March 2023].
- Maguire AM et al. Ophthalmology 2019;126;1273–1285.